A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12939429.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.
Medical subject headings
- Adrenoleukodystrophy
- Cobra Neurotoxin Proteins